BS_D4PJYHZ2
Neurofibroma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Neurofibroma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Neurofibroma
- overall_survival_months
- 8.015768725361367
- age_years
- 12.786
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.446
- ANGIOGENESIS+0.441
- APICAL_JUNCTION+0.402
- COAGULATION+0.399
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.386
- IL6_JAK_STAT3_SIGNALING+0.379
- INTERFERON_GAMMA_RESPONSE+0.375
- WNT_BETA_CATENIN_SIGNALING+0.370
- APICAL_SURFACE+0.366
- MYOGENESIS+0.335
Top 10 suppressed
- E2F_TARGETS-0.534
- MTORC1_SIGNALING-0.492
- G2M_CHECKPOINT-0.474
- OXIDATIVE_PHOSPHORYLATION-0.467
- PROTEIN_SECRETION-0.451
- MYC_TARGETS_V1-0.444
- SPERMATOGENESIS-0.354
- UNFOLDED_PROTEIN_RESPONSE-0.280
- PANCREAS_BETA_CELLS-0.223
- MYC_TARGETS_V2-0.215
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_5P3CZQV8 | Neurofibroma | — | 0.953 |
| 2 | BS_Z28VKGNS | Neurofibroma | — | 0.943 |
| 3 | BS_FQX1PRAJ | Neurofibroma | — | 0.940 |
| 4 | BS_TQ5QHR17 | Neurofibroma | — | 0.938 |
| 5 | BS_69V8P8A0 | Neurofibroma | — | 0.927 |
| 6 | BS_TAHV8N04 | Neurofibroma | — | 0.925 |
| 7 | BS_FRM9TG02 | Neurofibroma | — | 0.924 |
| 8 | BS_GDHH6T5A | Neurofibroma | — | 0.923 |
| 9 | TCGA-A2-A0CO-01A-13R-A22K-07 | — | A | 0.916 |
| 10 | MDT-AP-1125 | Med | Medulloblastoma | 0.910 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.446 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.441 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.402 | Inavolisib | — uncovered |
| COAGULATION | 0.399 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.386 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.379 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.375 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.370 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.366 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.335 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.332 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.292 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.284 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.279 | Inavolisib | — uncovered |
| COMPLEMENT | 0.251 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.239 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.227 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.208 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.205 | Idelalisib | — uncovered |